Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
How we came to be: Scientists get first look at the evolution of early complex animals - 2Lego's $650 Pokémon set is already sold out as demand, preorders surge
- 3The most effective method to Refresh the Infotainment Framework in the Volvo XC40
- 4Remain Fit: Powerful Wellness and Work-out Schedules for a Better You
- 5Polar bears are rewiring their own genetics to survive a warming climate
- Best Getaway destination: Ocean side, Mountain, or City
- 7 Delightful Ferris Wheels, Do You Like Them?
- SpaceX's 1st 'Version 3' Super Heavy Starship booster buckles under pressure during initial tests
- The most effective method to Succeed in Your Profession with a Web based Advertising Degree
- Why most Jewish Israelis back the death penalty for terrorists
- Find the Captivating Professional flowerbeds of the US
- European Travel Objections for 2024
- German finance minister seeks better market access in China talks
- Cyclone causes blackout, flight chaos in Brazil's Sao Paulo
